Cochrane Abstracts
Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Long‐term Proton Pump Inhibitor (PPI) Use and the Development of Gastric Pre‐malignant Lesions." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431008/all/Long‐term_proton_pump_inhibitor__PPI__use_and_the_development_of_gastric_pre‐malignant_lesions.
Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431008/all/Long‐term_proton_pump_inhibitor__PPI__use_and_the_development_of_gastric_pre‐malignant_lesions. Accessed January 24, 2026.
Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431008/all/Long‐term_proton_pump_inhibitor__PPI__use_and_the_development_of_gastric_pre‐malignant_lesions
Long‐term Proton Pump Inhibitor (PPI) Use and the Development of Gastric Pre‐malignant Lesions [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 January 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431008/all/Long‐term_proton_pump_inhibitor__PPI__use_and_the_development_of_gastric_pre‐malignant_lesions.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions
ID - 431008
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431008/all/Long‐term_proton_pump_inhibitor__PPI__use_and_the_development_of_gastric_pre‐malignant_lesions
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
